Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2 [personal view].
Options
BORIS DOI
Date of Publication
June 2021
Publication Type
Article
Division/Institute
Author
Meyerowitz, Eric A | |
Richterman, Aaron | |
Bogoch, Isaac I | |
Cevik, Muge |
Series
Lancet infectious diseases
ISSN or ISBN (if monograph)
1473-3099
Publisher
Elsevier
Language
English
Publisher DOI
PubMed ID
33301725
Description
People with persistently asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection experience no symptoms throughout the course of infection, and pre-symptomatic individuals become infectious days before they report symptoms. Transmission of SARS-CoV-2 from individuals without symptoms contributes to pandemic spread, but the extent of transmission from persistently asymptomatic individuals remains unknown. We describe three methodological issues that hinder attempts to estimate this proportion. First, incomplete symptom assessment probably overestimates the asymptomatic fraction. Second, studies with inadequate follow-up misclassify pre-symptomatic individuals. Third, serological studies might identify people with previously unrecognised infection, but reliance on poorly defined antibody responses and retrospective symptom assessment might result in misclassification. We provide recommendations regarding definitions, detection, documentation, and follow-up to improve the identification and evaluation of people with persistently asymptomatic SARS-CoV-2 infection and their contacts. Accurate characterisation of the persistently asymptomatic fraction of infected individuals might shed light on COVID-19 pathogenesis and transmission dynamics, and inform public health responses.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
Meyerowitz_LancetInfectDis_2020_AAM.pdf | Adobe PDF | 405.79 KB | Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND 4.0) | accepted | |||
Meyerowitz_LancetInfectDis_2021.pdf | Adobe PDF | 3.1 MB | publisher | published |